Diomed (AMEX:DIO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Diomed Charts. Click Here for more Diomed Charts.](/p.php?pid=staticchart&s=A%5EDIO&p=8&t=15)
Diomed Holdings, Inc. (AMEX:DIO), a leading developer and marketer of
minimally-invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLT®)
for varicose veins, today announced that it has appointed William D.
Allan as Managing Director of its wholly owned subsidiary, Diomed Ltd.,
Cambridge, England effective November 1, 2006.
In this role, Mr. Allan will be responsible for planning, developing and
implementing corporate programs related to the management of Cambridge
operations including research and development, manufacturing, quality,
regulatory, finance, information technology, human resources, global
customer support and administration as well as sales and marketing
outside of the Americas.
Prior to joining Diomed, Mr. Allan spent fifteen years with Smith &
Nephew in various responsibilities including sales, marketing, business
development and general management. Most recently, he was Global Vice
President – Marketing for Smith & Nephew Wound
Management with strategic responsibilities for marketing through 33
countries.
“We are thrilled to have Bill join our
executive management team,” stated James
Wylie, President & CEO of Diomed Holdings, Inc. “He
is a proven global healthcare professional with both capital and
consumable product experience. Importantly, Bill’s
solid operating experience combined with extensive sales and marketing
experience in Diomed’s targeted growth markets
will help Diomed drive offshore growth.”
Mr. Allan studied Dental Surgery at the University of Edinburgh and
practiced as a Dental Surgeon in South Africa and in the UK. He has an
MBA from the University of Cape Town and AMP from Insead Business School
in Paris. Mr. Allan holds dual British and South African citizenships.
“I am very excited indeed to join Diomed at
this time,” commented Mr. Allan. “I
look forward to providing leadership to the UK and international
business teams, as we focus on driving sustainable growth and realizing
the full potential for the business.”
About Diomed
Diomed develops and commercializes minimal and micro-invasive medical
procedures that use its proprietary laser technologies and disposable
products. Diomed’s EVLT®
laser vein ablation procedure is used in varicose vein treatments.
Diomed also provides photodynamic therapy (PDT) for use in cancer
treatments, and dental and general surgical applications. The EVLT®
procedure and the Company’s related products
were cleared by the United States FDA in January of 2002. Along with
lasers and single-use procedure kits for its EVLT®
laser vein treatment, the Company provides its customers with state of
the art physician training and practice development support. Additional
information is available on the Company’s
website: www.evlt.com.
EVLT® is a registered trademark of Diomed
Inc., Andover, MA.
Safe Harbor
Safe Harbor statements under the Private Securities Litigation Reform
Act of 1995: Statements in this news release looking forward in time
involve risks and uncertainties, including the risks associated with
trends in the products markets, reliance on third party distributors in
various countries outside the United States, reoccurring orders under
OEM contracts, market acceptance risks, technical development risks and
other risk factors. These statements relate to our future plans,
objectives, expectations and intentions. These statements may be
identified by the use of words such as "may," "will," "should,"
"potential," "expects," "anticipates," "intends," "plans," "believes"
and similar expressions. These statements are based on our current
beliefs, expectations and assumptions and are subject to a number of
risks and uncertainties. Our actual results could differ materially from
those discussed in these statements.
Our Annual Report on Form SEC 10-KSB/A (the "Annual Report") contains a
discussion of certain of the risks and uncertainties that affect our
business. We refer you to the "Risk Factors" on pages 23 through 38 of
the Annual Report for a discussion of certain risks, including those
relating to our business as a medical device company without a
significant operating record and with operating losses, our risks
relating to our commercialization of our current and future products and
applications and risks relating to our common stock and its market
value. Diomed disclaims any obligation or duty to update or correct any
of its forward-looking statements.
Diomed Holdings, Inc. (AMEX:DIO), a leading developer and marketer
of minimally-invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLT(R)) for varicose veins, today
announced that it has appointed William D. Allan as Managing Director
of its wholly owned subsidiary, Diomed Ltd., Cambridge, England
effective November 1, 2006.
In this role, Mr. Allan will be responsible for planning,
developing and implementing corporate programs related to the
management of Cambridge operations including research and development,
manufacturing, quality, regulatory, finance, information technology,
human resources, global customer support and administration as well as
sales and marketing outside of the Americas.
Prior to joining Diomed, Mr. Allan spent fifteen years with Smith
& Nephew in various responsibilities including sales, marketing,
business development and general management. Most recently, he was
Global Vice President - Marketing for Smith & Nephew Wound Management
with strategic responsibilities for marketing through 33 countries.
"We are thrilled to have Bill join our executive management team,"
stated James Wylie, President & CEO of Diomed Holdings, Inc. "He is a
proven global healthcare professional with both capital and consumable
product experience. Importantly, Bill's solid operating experience
combined with extensive sales and marketing experience in Diomed's
targeted growth markets will help Diomed drive offshore growth."
Mr. Allan studied Dental Surgery at the University of Edinburgh
and practiced as a Dental Surgeon in South Africa and in the UK. He
has an MBA from the University of Cape Town and AMP from Insead
Business School in Paris. Mr. Allan holds dual British and South
African citizenships.
"I am very excited indeed to join Diomed at this time," commented
Mr. Allan. "I look forward to providing leadership to the UK and
international business teams, as we focus on driving sustainable
growth and realizing the full potential for the business."
About Diomed
Diomed develops and commercializes minimal and micro-invasive
medical procedures that use its proprietary laser technologies and
disposable products. Diomed's EVLT(R) laser vein ablation procedure is
used in varicose vein treatments. Diomed also provides photodynamic
therapy (PDT) for use in cancer treatments, and dental and general
surgical applications. The EVLT(R) procedure and the Company's related
products were cleared by the United States FDA in January of 2002.
Along with lasers and single-use procedure kits for its EVLT(R) laser
vein treatment, the Company provides its customers with state of the
art physician training and practice development support. Additional
information is available on the Company's website: www.evlt.com.
EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.
Safe Harbor
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: Statements in this news release looking forward in
time involve risks and uncertainties, including the risks associated
with trends in the products markets, reliance on third party
distributors in various countries outside the United States,
reoccurring orders under OEM contracts, market acceptance risks,
technical development risks and other risk factors. These statements
relate to our future plans, objectives, expectations and intentions.
These statements may be identified by the use of words such as "may,"
"will," "should," "potential," "expects," "anticipates," "intends,"
"plans," "believes" and similar expressions. These statements are
based on our current beliefs, expectations and assumptions and are
subject to a number of risks and uncertainties. Our actual results
could differ materially from those discussed in these statements.
Our Annual Report on Form SEC 10-KSB/A (the "Annual Report")
contains a discussion of certain of the risks and uncertainties that
affect our business. We refer you to the "Risk Factors" on pages 23
through 38 of the Annual Report for a discussion of certain risks,
including those relating to our business as a medical device company
without a significant operating record and with operating losses, our
risks relating to our commercialization of our current and future
products and applications and risks relating to our common stock and
its market value. Diomed disclaims any obligation or duty to update or
correct any of its forward-looking statements.